|
Syncona Ltd - London-based healthcare investor - Net asset value at June 30 is 184.6 pence per share, down 1.0% from 186.5p on March 31. NAV total return also was negative 1.0% for the recent three months, Syncona’s financial first quarter. Notes performance was hurt by ‘negative foreign exchange movements’ across its life science portfolio. This is valued at £628.7 million on June 30, up 4.0% from £604.6 million on March 31. Chief Executive Officer Chris Hollowood says: ‘We have seven clinical-stage companies across our increasingly diversified portfolio, and we are confident in their ability to execute on their key milestones. We believe the portfolio offers a significant opportunity to realise our ambition to bring transformational treatments to patients and deliver strong risk-adjusted returns to shareholders.’ Current stock price: 152.00 pence 12-month change: down 27% Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
